Sinopharm CNBG has just launched a new phase-3 production site for its COVID-19 vaccines in Chinese capital Beijing. The company says it now expects to increase annual vaccine production to 5 billion doses. In June, CGTN's reporter Liu Yang spoke to Wang Hui, general manager and director of CNBG's Beijing Institute of Biological Products. She talked about the significance of putting the phase-3 production site into operation, the allocation plan, vaccine's efficacy to the Delta variant and herd immunity in China.